Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) EBITDA Margin (2020 - 2025)

Roivant Sciences' EBITDA Margin history spans 6 years, with the latest figure at 16966.13% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1392354.0% year-over-year to 16966.13%; the TTM value through Dec 2025 reached 20987.61%, down 4151140.0%, while the annual FY2025 figure was 3453.32%, 1720025.0% down from the prior year.
  • EBITDA Margin reached 16966.13% in Q4 2025 per ROIV's latest filing, up from 19492.87% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 32948.56% in Q4 2023 to a low of 19492.87% in Q3 2025.
  • Average EBITDA Margin over 5 years is 3642.27%, with a median of 3042.59% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: surged 3516576bps in 2023, then plummeted -3599115bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 1010.73% in 2021, then plummeted by -119bps to 2217.2% in 2022, then skyrocketed by 1586bps to 32948.56% in 2023, then plummeted by -109bps to 3042.59% in 2024, then plummeted by -458bps to 16966.13% in 2025.
  • Per Business Quant, the three most recent readings for ROIV's EBITDA Margin are 16966.13% (Q4 2025), 19492.87% (Q3 2025), and 13130.05% (Q2 2025).